Deal Size Increased to $225M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
The deal size was increased to $225M from $150M and priced below last closing price of $10.05. JPMorgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 15.080
Low
2.00
Averages
5.50
High
11.00
Current: 15.080
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Notification: Kahn Swick & Foti has informed investors that Erasca, Inc. is facing a class action lawsuit aimed at recovering losses for those who purchased shares between January 14, 2025, and April 26, 2026, highlighting potential legal compliance risks for the company.
- Lawsuit Background: The lawsuit alleges that Erasca and certain executives failed to disclose material information during the class period, violating federal securities laws, particularly concerning misleading statements about the clinical data for its ERAS-0015 product, which could lead to significant investor losses.
- Legal Proceedings Update: The case is pending in the United States District Court for the Southern District of California, with investors required to apply by August 10, 2026, to be appointed as lead plaintiffs, reflecting the proactive engagement of investors in legal proceedings.
- Law Firm Background: Kahn Swick & Foti is one of the nation's premier boutique securities litigation firms, ranked among the top ten nationally based on total settlement value in the past year, demonstrating its expertise and influence in protecting investor rights.
See More
Erasca Faces Class Action Lawsuit Risks
- Class Action Initiation: Purchasers of Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, which could expose the company to significant legal and financial risks.
- Stock Price Volatility: Following the April 27, 2026, disclosure of patent infringement claims against ERAS-0015 from Revolution Medicines, Erasca's stock price fell nearly 11%, and subsequent preliminary Phase I clinical data reporting led to an additional decline of over 48%, indicating strong market concerns regarding the product's prospects.
- Clinical Data Controversy: In reporting preliminary Phase I clinical data for ERAS-0015, Erasca noted the death of a patient one month after treatment initiation and emphasized that comparisons with other candidates were based on cross-study analyses rather than direct comparisons, potentially undermining investor confidence in its product pipeline.
- Legal Proceedings Management: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can seek lead plaintiff status, which allows them to represent other shareholders in the lawsuit, potentially impacting the company's future legal liabilities and financial health.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a market cap loss exceeding $2.8 billion, indicating severe market concerns over product safety and intellectual property.
- Legal Action: The securities class action aims to represent investors who purchased Erasca stock between January 14, 2025, and April 26, 2026, alleging that the company misled the market regarding ERAS-0015's intellectual property protection, potentially leading to significant investor losses.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 to RevMed's RMC-6236, exposing the company to intellectual property disputes and exacerbating investor confidence issues regarding its product.
- Patient Adverse Event: On the same day the lawsuit was disclosed, Erasca revealed that a patient treated with ERAS-0015 suffered an adverse event and died a month later, intensifying market skepticism about the product's safety and further impacting stock performance.
See More
Erasca Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Erasca, Inc., aiming to recover damages for investors who purchased securities between January 14, 2025, and April 26, 2026, indicating strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that Erasca made false and misleading statements during the class period, failing to disclose that ERAS-0015's preclinical data was based on improper comparisons, which could jeopardize patent and trade secret protections, highlighting significant deficiencies in the company's disclosure practices.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by August 10, 2026, emphasizing the legal team's commitment to securing compensation for investors and the importance of investor rights advocacy.
- No-Cost Representation: Bronstein, Gewirtz & Grossman, LLC offers contingency fee representation, charging fees only upon successful recovery, which reduces the financial burden on investors participating in the lawsuit and enhances their confidence in pursuing claims.
See More
Erasca Faces Securities Class Action After 48% Stock Plunge
- Stock Plunge: Erasca's shares plummeted by $9.25 (-48%) following allegations of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in the company's future prospects.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors regarding its ERAS-0015 treatment, with the class period spanning from January 14, 2025, to April 26, 2026, potentially affecting a large number of shareholders' rights.
- Patent Dispute: The company faces accusations of improperly comparing its ERAS-0015 to Revolution Medicines' RMC-6236, which could lead to intellectual property disputes and further exacerbate market uncertainty surrounding its product claims.
- Patient Safety Concerns: The disclosure of a patient's adverse event and subsequent death after receiving ERAS-0015 has heightened investor fears regarding the safety profile of the treatment, which may impact future clinical trials and market acceptance.
See More
Erasca Faces Class Action Lawsuit Risks
- Lawsuit Background: Erasca, Inc. is facing a class action lawsuit due to allegations that its drug candidate ERAS-0015 infringes on Revolution Medicines' patent, impacting investors who purchased shares between January 14, 2025, and April 26, 2026.
- Stock Price Plunge: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, closing at $19.15 per share after receiving a legal letter, resulting in significant investor losses.
- Clinical Data Disclosure: On the same day, Erasca reported preliminary clinical data for ERAS-0015, revealing a patient death approximately one month after treatment initiation, causing the stock to plummet further by $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026.
- Legal Allegations: The class action lawsuit alleges that throughout the class period, Erasca failed to disclose critical adverse facts regarding ERAS-0015, misleading investors about the company's business prospects and exposing them to substantial legal and financial risks.
See More
Erasca Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Notification: Kahn Swick & Foti has informed investors that Erasca, Inc. is facing a class action lawsuit aimed at recovering losses for those who purchased shares between January 14, 2025, and April 26, 2026, highlighting potential legal compliance risks for the company.
- Lawsuit Background: The lawsuit alleges that Erasca and certain executives failed to disclose material information during the class period, violating federal securities laws, particularly concerning misleading statements about the clinical data for its ERAS-0015 product, which could lead to significant investor losses.
- Legal Proceedings Update: The case is pending in the United States District Court for the Southern District of California, with investors required to apply by August 10, 2026, to be appointed as lead plaintiffs, reflecting the proactive engagement of investors in legal proceedings.
- Law Firm Background: Kahn Swick & Foti is one of the nation's premier boutique securities litigation firms, ranked among the top ten nationally based on total settlement value in the past year, demonstrating its expertise and influence in protecting investor rights.
See More
Erasca Faces Class Action Lawsuit Risks
- Class Action Initiation: Purchasers of Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, which could expose the company to significant legal and financial risks.
- Stock Price Volatility: Following the April 27, 2026, disclosure of patent infringement claims against ERAS-0015 from Revolution Medicines, Erasca's stock price fell nearly 11%, and subsequent preliminary Phase I clinical data reporting led to an additional decline of over 48%, indicating strong market concerns regarding the product's prospects.
- Clinical Data Controversy: In reporting preliminary Phase I clinical data for ERAS-0015, Erasca noted the death of a patient one month after treatment initiation and emphasized that comparisons with other candidates were based on cross-study analyses rather than direct comparisons, potentially undermining investor confidence in its product pipeline.
- Legal Proceedings Management: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can seek lead plaintiff status, which allows them to represent other shareholders in the lawsuit, potentially impacting the company's future legal liabilities and financial health.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a market cap loss exceeding $2.8 billion, indicating severe market concerns over product safety and intellectual property.
- Legal Action: The securities class action aims to represent investors who purchased Erasca stock between January 14, 2025, and April 26, 2026, alleging that the company misled the market regarding ERAS-0015's intellectual property protection, potentially leading to significant investor losses.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 to RevMed's RMC-6236, exposing the company to intellectual property disputes and exacerbating investor confidence issues regarding its product.
- Patient Adverse Event: On the same day the lawsuit was disclosed, Erasca revealed that a patient treated with ERAS-0015 suffered an adverse event and died a month later, intensifying market skepticism about the product's safety and further impacting stock performance.
See More
Erasca Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Erasca, Inc., aiming to recover damages for investors who purchased securities between January 14, 2025, and April 26, 2026, indicating strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that Erasca made false and misleading statements during the class period, failing to disclose that ERAS-0015's preclinical data was based on improper comparisons, which could jeopardize patent and trade secret protections, highlighting significant deficiencies in the company's disclosure practices.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by August 10, 2026, emphasizing the legal team's commitment to securing compensation for investors and the importance of investor rights advocacy.
- No-Cost Representation: Bronstein, Gewirtz & Grossman, LLC offers contingency fee representation, charging fees only upon successful recovery, which reduces the financial burden on investors participating in the lawsuit and enhances their confidence in pursuing claims.
See More
Erasca Faces Securities Class Action After 48% Stock Plunge
- Stock Plunge: Erasca's shares plummeted by $9.25 (-48%) following allegations of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in the company's future prospects.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors regarding its ERAS-0015 treatment, with the class period spanning from January 14, 2025, to April 26, 2026, potentially affecting a large number of shareholders' rights.
- Patent Dispute: The company faces accusations of improperly comparing its ERAS-0015 to Revolution Medicines' RMC-6236, which could lead to intellectual property disputes and further exacerbate market uncertainty surrounding its product claims.
- Patient Safety Concerns: The disclosure of a patient's adverse event and subsequent death after receiving ERAS-0015 has heightened investor fears regarding the safety profile of the treatment, which may impact future clinical trials and market acceptance.
See More
Erasca Faces Class Action Lawsuit Risks
- Lawsuit Background: Erasca, Inc. is facing a class action lawsuit due to allegations that its drug candidate ERAS-0015 infringes on Revolution Medicines' patent, impacting investors who purchased shares between January 14, 2025, and April 26, 2026.
- Stock Price Plunge: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, closing at $19.15 per share after receiving a legal letter, resulting in significant investor losses.
- Clinical Data Disclosure: On the same day, Erasca reported preliminary clinical data for ERAS-0015, revealing a patient death approximately one month after treatment initiation, causing the stock to plummet further by $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026.
- Legal Allegations: The class action lawsuit alleges that throughout the class period, Erasca failed to disclose critical adverse facts regarding ERAS-0015, misleading investors about the company's business prospects and exposing them to substantial legal and financial risks.
See More
